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The Alzhcimcr-like state of tau protein includes phosphorylation by a proline-directed Ser/Thr kinasc present in normal or pathological human 
brain. Extending earlier results on MAP kinase, WC show hcrc that the prolinc-dircctcd kinasc, GSK3, can induct an Alzhcimer-like immune 
response involving several distinct and phosborylalablc epitopcs at &-Pro motifs, as well as a gel mobility shift, similar 10 MAP kinasc. Both 
kinases bchavc like microtubule-nssociotcd proteins in that ~hcy co-purify through cycles of assembly and disassembly, and boih kinascs are directly 
associated with paired helical filaments. 
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1. INTRODUCTION 
Tau protein represents a major component of the 
paired helical filaments (PHF) of Alzheimer’s disease 
(for reviews see [l-3]). A major goal of Alzheimer re- 
search is to find out in what way pathological tau differs 
from normal tau. One sensitive method is the use of 
monoclonal antibodies that distinguish between PHF 
tau and normal tau. We have recently investigated the 
‘Alzheimer-like state’ of tau induced by a certain type 
of phosphorylation, dominated by phosphorylated Ser- 
Pro and Thr-Pro motifs [4]. This state can be detected 
by several independent criteria, such a.s PHF-specific 
antibodies with distinct epitopes, and a particular shift 
in electrophoretic mobility [5&i], and it can be induced 
by a kinase activity in human brain extract or by puri- 
lied MAP kinase [7]. These results suggested that MAP 
kinase could be a key enzyme in the pathological phos- 
phorylation of tau protein. 
Building on these observations we branched out in 
two directions. Firstly, since most of the abnormal 
phosphorylated motifs were of the Ser-Pro type we 
tested other prolinc-directed kinases. We had found ear- 
lier that the cell cycle kinase, cdc2, combined with either 
cyclin A or B, caused only a small degree of phosphoryl- 
ation and no Alzheimer-like immune response [7]. We 
then turned to GSK3, a kinase involved in the control 
of insulin-stimulated signal transduction [S,9], and in 
this paper we show that the effect of this kinase resem- 
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bles that of MAP kinase, making it another candidate 
for the pathological phosphorylation of tau. Secondly, 
we show that both GSK3 and MAP kinase copurify 
with cycles of microtubule assembly, making them gen- 
uine microtubule-associated proteins, and that both arc 
associated with Alzheimer PHFs. Both isoforms of 
GSK3 (a, 51 kDa; B, 45 kDa) have similar effects. 
2. MATERIALS AND METHODS 
The methods used here have been dcsctibcd in recent publications 
so only some key points will be repeated. Normal human or bovine 
brain tau was prepared as described in [lo], Recombinant human tau 
proteins were derived from the cDNA clones of Gocduti et al. [11.12] 
and expressed in E. coli [13], using derivatives of the PET expression 
vector [141. Point mutants were made by PCR [5,6]. Phosphorylalian 
by the brain kinnsc activity was done following [S]. Fig. la shows a 
diagram of the domain structure of htau40 and its main phosphoryla- 
tion sites. 
GSK3 (a and /? isoforms) were purified from bovine brain as in 
Vandcnhccee t al. [8] with an additional Mono S chromaiography 
step which separates the two &forms. Most expcrimenis described 
bcrc were done with immunoprecipitntcs of GSK3-e on TSK lxzds. 
but control cxperimcnts with the/I isoform showed the same behavior. 
Polyclonal anti-peptide antibodies to the u and@ isoforms ofGSK3 
were raised in rabbits and affmity purified on peptide columns [IS]. 
Immunoprccipitatos f GSK3 were prepared from PC-12 cytosols in 
20 mM Tris-HCI, 1% NP-40, 1 mM PMSF, 2,qgml aprotinin. I @ml 
lcupcptin and 0.2 p@rnl pcpstatin. 100 pl ofcytosolr wcrc incubated 
with 1 pl a- orfl-GSK antibodies (I mg/ml) or control rabbit unlibod- 
its and incubated for 4 h at 4OC; 5 ~1 of TSK-protein A beads wcrc 
addLti and incubated for 1 h, and fmally the beads wcrc wsshcd with 
10 m&ml BSA in 20 mM Tris-HCI, 0.5 M LiCl in Tris buffer, and 20 
mM HEPES. pH 7.2, with IO mM MgC& and I mM DTT. In phos- 
phoryladon assays. 2pl ofpcllc~s were incubated with 8~1 of substmtc 
(3pM) in 40 mM HEPES, pH 7.2, IO mM M#& 2 mM ATP, 2 mM 
EGTA. 0.5 mM DTT and 1 mM PMSF. 
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Fig. 1. (a) Bar diigram of htau40, showing the location of all Ser-Ro 
and Thr-Pm motifs. The numbering follows that of htau40 [14- The 
two hatched boxes near the N-terminus (29 residues each) are inserts 
that may be absent in smatler tau isoforms (e.g. both absent in htau23). 
The four boxes in theC-terminal halfindicatethemictotubule-binding 
tqeats. Repeat 2 may be absent (e.g. in htau23. htau37, htau3Y). MAY 
kinase can phosphurylate all Ser-Pro or Thr-Pro motifs (7J. GSK3 
phosphoty\ates mainly Ser-199, -202, -235, -396, -404, all followed by 
Pro. (b) Bar diagram of htau40 with epitopes of antibodies sensitive 
to the Alzheimer-like state of tau (see (5,6]. +P or -P means phospho- 
rylation or not. TAUl requires dephosphoryhted Ser-199 and -202, 
the PHF-specific antibody, AT%, requires both phosphorylated. 
SM133 xequircs dephosphorylated Ser-235, SMl31 requires 
phosphorylated Ser-396 and -404. SMI34 is conformation sensitive 
and requires phosphorylated Se-Pro motifs on either side of the 
repeat region. 
Antibodies against tau were obtained from Dr. L. Binder (TAtit. 
[lq), Innogenetics SA (AT& [t?)), and Sternbecger MonocIonals Inc. 
(SMI 31. 33. 34 [ISl). We had previously determined their epitopes 
[%a; they are digrammed in Fig. lb. TAU1 and SM133 react with 
normal (or recombinant unphosphorylated) tau; AT8, S&i131 and 
SM13Q react with Alzheimer PHFs. or with tau phosphorylated by 
MAP kinase or the brain extract. 
3. RESULTS 
3.1. Tkm-course of phosphorykztion and antibody re- 
sponse induced by GSK3 
The Alzheimer-like state of tau protein can be as- 
sessed by a combination of several criteria; a gel shift, 
phosphorylation, and reactivity with antibodies that 
distinguish between PHF-tau and normal tau. The Alz- 
heimer-like gel shift takes place in three main stages 
which can be induced by a kinase activity in brain ex- 
tract [!jj, purified MAP kinase, but not by the cell cycle 
kinase cdd [7j. The extract activity and MAP kinase 
phosphoryiate mainly &r-Pro or Thr-Pro motifs [4]; in 
the case of activated MAP kinase this reaches 210 Pi 
per htau23 molecule, approaching the total number cf 
14 &r-Pro and Thr-Pro motifs, while the extract kinase 
/ .*, 
In our s&t$h for &her p~oline-di+~ kjnpes we 
have repeated th&e e~pe+ments with GSIU (alias phos- 
phatase activating factor FA [3]). Fig.:% shov a time- 
course of phosphorylation of htau40 with GSKS,’ and 
the corresponding autoradiogram and immunoblots. In 
most respects the behavior is similar to that obtained 
with the brain kinase activity or with purified MAP 
kinase (compare Figs. 2 and 3 of (61, and Fig. 7 of [?I). 
Phosphorylation induces a gel shift in three main stages; 
it incorporates -4 Pi, it induces the reactivity of anti- 
bodies ATS, SM134, and SMI31, but reduces the reac- 
tivity of TAUl and SMI33. 
3.2. Phosphorylation sites of GSKT3 on tau 
The main phosphorylation sites can be determined 
from antibody epitopes and point mutants (Fig. 2). The 
epitopes of ATS, TAUl, and the SMI antibodies and 
their phosphorylation dependence has been determined 
previczlsly (Fig. lb, and see 15,6]). TAUl requires that 
both Ser-199 and Ser-202 are unphosphorylated, AT8 
requires them both phosphorylated& Thus when only 
one of the two serines is phosphorylated these antibod- 
ies do not react. This means that Ser-149 and Ser-202 
both become phospborylated during stage 2 (Fig. 2, 
panels 3,4}. Similarly, antibody SMI3l requires the 
phosphorylation of both Ser-396 and Ser-404, which 
means that both serines become phosphorylated rapidly 
during stage 1 (Fig. 2, panel 6). SW33 reacts only when 
Ser-235 is unphasphorylated so the gradual loss of reac- 
tivity means that this residue becomes phosphorylated 
only slowly (panel 7). Together these residues would 
account for 5 pi, but only -4 Pi are observed by autora- 
diography, indicating that not all of these serines are 
phosphorylated at iOO%. There are some subtle dif%tr- 
ences in the time-course of the immune response, corn- 
pared to MAP kinase. For example, the SM13 1 reactiv- 
ity sets in early and precedes that of AT8 and SM134, 
while the reactivity of SM133 persists for a longer time, 
indicating that the mode of action of GSK3 is not iden- 
tical to that of MAP kinase. 
Additional information can be obtained by point mu- 
tations. As shown previously, the initial strong mobility 
shift induced by the kinase activity from brain extracts 
and by MAP kinase is due to the phosphorylation of 
Ser-404 (Fig. 6 of [4])_ The same is true for GSK3, as 
illustrated in Fig. 3 (lanes l-3). When Se+404 is mu- 
tated into Ala, the initial rapid shift disappears, and 
initial phosphorylation is reduced to a low level (Fig. 3, 
compare lanes 2 and 5). 
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Fig. 2. Time-eoutse of phosphorylation of htau4U By ti~3h> anu 
immune response. (Panel 1) SDS-PAGE of htau40 after incubation 
with the kinase between 0 and 20 h at 37%. The minor lower band 
in lane 1 is a fragment. Note the progrcssivc shiR to higher M, vatucs, 
similar to the effeas of brain extract and MAP kinase. (Panel 2) 
Autoradiography. panel 3) Immunoblot with the antibody TAIJI 
whose reactivity is lost after -2 h (foltowing the phosphorylation of 
Ser-199 and Ser-202). (Panel 4) Immunoblot with the PHF-specific 
antibody AT8 whose reactivity requires the phosphorylation of Ser- 
199 and Ser-202. (Panel 5) lmmunoblot with antibody SMI34 (confor- 
mation sensitive and against phosphotylatcd Ser). Panel 6) Blot with 
SMI31 (epitope indudes phosphorylatcd W-396 and Ser-404). (Panel 
7) Blot with antibody SM133 which rcquiffs a dephosphorylatcd Ser- 
235. There are some differences with respect to phosphorylation by 
MAP kinase or the brain extract. The SMI33 staining persists for a 
long period, suggesting that Scr-235 is only slowly phosphorylated by 
GSK3. The staining of SMl3l appears very quickly. before that of 
AT8 or SMI34. showing that Ser-396 and Ser404 are among the 
earliest targets of GSK3. 
Another conclusion from the immunoblots is that 
GSK3 strongly prefers &-Pro motifs, in contrast to 
MAP kinase which also affects Thr-Pro. This can be 
concluded because the -4 Pi incorporated are needed 
to account for the phosphorylated epitopes- To test this 
we made construct APll, a derivative of htau23 in 
which aIf 5 !kr- Pro are replaced with Ala-Pro (Fig. 4, 
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Fig. 3. Mobility shiftof hta$3 I& III&& htadfA468 U&I phm- 
phorylation with GSKX A, SDS gel B,‘&totidio&a%ti 1-3, 
htau23 unphosphorylated and’phosphorylated for 2 or 20 h. Note the 
pronouncedshiftand thecIca+t~rporationofphosphate. Lana4-6, 
mutant Ser-404+AIa, unphosphotylated and phosphorylatd for 2 
and 20 h. The shift after 2 h is much smaller and the degree UT 
phosphorylation much lower. This shows that the first strongshiftand 
phosphorylation is at Ser-404, similar to MAP kinasc and the brain 
extract kinase activity. 
middle). API 1 is phosphorylated only to a minimal ex- 
tent, CO. 1 Pi per molecule, confirming that the Thr-Pro 
motifs remain largely unphosphorylated. The same re- 
sult is obtained with construct API7 (all 6 Ser-Pro and 
8 Thr-Pro replaced by Ala-Pro, Fig. 4, top). Another 
construct, K18, containing only the 4 repeats (Fig. 4, 
bottom), is also not phosphorylated, indicating that no 
mqior sites are within the microtubule binding region. 
Thus, GSK3 and MAP kinase are similar in that they 
are both proline directed, but MAP kinase is more ac- 
tive with respect to Thr-Pro motifs. 
3.3. GSK3 and MAPkinase are associu& t&h microtu- 
buies and wifh PHFs 
Considering that tau is a microtubuIe-associated pro- 
tein one might expect that kinases that phosphorytate 
tau might be localized in the vicinity of microtubules. 
An example is the regulatory subunit of PKA which is 
bound to MAP2 [NJ. We therefore tested whether MAP 
kinase or GSK3 were MAPS according to the usual 
criterion of co-purification through repeated cycles of 
assembly and disassembly. This was indeed the case. 
Fig. Sb shows that both the p42 and p44 isofonns of 
MAP kinase co-purified with porcine brain microtu- 
bules. Fig. 5c,d demonstrates the same for the case of 
GSK3 a and j9. Interestingly, the microtubule-associ- 
ated MAP kinase was not in an activated state since it 
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Fig. 4. Diagrams of tau constructs. Top, AP17, a derivative ofhtnu23 
with all Ser-Pro or Thr-Pro motifs altered into Ala-Pro. Middle, 
API 1, only Ser-Pro motifs changed into Ala-Pro. Bottom, K18, only 
4 repeats of mu (derived from htnu40). 
was not phosphorylated on Tyr (as judged by im- 
munoblotting, not shown). 
Considering this result we asked whether the kinases 
were also associated with Alzheimer PHFs. The im- 
munoblots of Fig. 6a demonstrate that GSK3 is present 
in normal and in Alzheimer brain in roughly equivalent 
amounts; the presence of MAP kinase was already 
shown earlier [7]. Moreover, the kinases co-purify di- 
rectly with PHFs isolated by two different procedures, 
following [ZO] (Fig. Gb, lane 1) and [21] (lane 2). 
The fact that GSK3 is associated with microtubules 
and PHFs and phosphorylates tau would suggest hat 
the kinase might be able to affect the interaction be- 
tween tau and microtubules. This would be in agree- 
ment with a common notion about the pathological 
effects of tau phosphorylation. However, to our sur- 
prise there was no influence on the binding. Fig. 7 shows 
the binding of htau23 to microtubules without phospho- 
rylation, with phosphorylation by GSK3, and by the 
kinase activity of the brain extract. In the latter case 
there is a strong reduction in affinity (as reported ear- 
lier, [4]), but the effect of GSK3 itself is minimal. 
4. DISCUSSION 
One goal of current Alzheimer research is to define 
the modes of phosphorylation of tau protein and how 
this relates to the ‘abnormal phosphorylation of tau in 
PHFs [22]. Tau can be phosphorylated by several com- 
mon kinases, such as PICA, PKC, CaMK, or CK II, in 
vitro 113,231, but in such cases the problem is to assess 
rl:c,,c: -diethi% these iii&~~bnb~OiX OCcili iii ‘Gi‘r’O ai WCll, 8; d 
whether they are normal or pathological. Conversely, 
several phosphorylation sites have been identified in 
PHFs [24,25], but the kinases responsible are not 
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Fig. 5. Co-polymerizntion of MAP kinase and GSK3 with porcine 
brain microtubulcs. (a) SDSgcl ofmicrotubule purification stages. Ex, 
bmin extract, supernatant nftcr first cold spin; S, supcrnatnnt of first 
hot spin (tubulin and MAPS not assembled into microtubules after 
warming to 37%); P, pellet of redissolved microtubules. The other 
lanes (S,P) show two further cycles of assembly and disassembly by 
tcmpraturc shifts (last pellet of microtubule protein was conccn- 
tratd). (b) Blat with anti-MAP kinasc, showing mninly the p42 
iroform and some of the p44 isoform. (c) Blot with mttiGSK3fi; note 
that this ttntibody shows some cross-reactivity with GSK3a. (d) Ulot 
wilh antLGSK3a. The blots show thnt both kindsesand their isoforms 
co-purify with the cycles of microtubule assembly. 
known. We have taken a hybrid approach in that we 
dcf;nc tRc ALI.&.-m.. I:La 1tdLl~,,,,~, -111.c s:;;te of :a:: by a set of severa! 
independent criteria, search for kinases that induce this 
state, and identify the phosphorylation sites. The crite- 
ria include (i) the reaction with several antibodies that 
Volume 314, number 3 FEBS LETTERS DiXember 1992 
Ml23 45 
ib) PHF-Tau 
1 2 
Fig. 6. (a) Identification of GSK3n and /s in rlormnl and Alaheimer 
brain extracts. M, markers; lane I, SDS Se1 of normal bmin extract; 
lane 2, immunoblot with anti-GSKa; lane 3, immunoblot with anti- 
GSK3p (with some cross-reactivity to a); lanes 4 and 5, same blots 
with Alzhcimer brain extracts. (b) lmmunoblot of PHI: tau prepared 
according to [20] in lane I and [21] in lane 2. The blot of lane I was 
first developed with anti-MAP kinnse, then stripped and devclopcd 
with anti-GSKa. The blot of lane 2 was first developed with Al250 
antibody (against mu), then stripped and developed with anti-GSKa. 
Similar results arc obtained with nnti-GSKP (not shown). 
discriminate between PHF tau and normal tau and are 
directed towards distinct epitopes, (ii) the phosphoryla- 
tion dependence of these antibodies, (iii) an electro- 
phoretic mobility shift of a particular magnitude. This 
approach allowed us to prepare a brain kinase activity 
inducing the required characteristics in tau. In the 
course of the work we defined the epitopcs of several 
antibodies, and in each case they were sensitive to phos- 
phorylation [5,6]. Sequencing showed that the main 
sites were of the Ser-Pro or Thr-Pro type [4], and this 
lead the way towards the identification of MAP kinase 
as one key enzyme which was capable of inducing the 
Alzheimer-like state of tau [7]. 
0 5 10 :5 
tau free [PM) 
Fig. 7. Binding curves of htau23 to microtubules (made from IO PM 
tubulin in the prescncc of 20pM tnxol). (m) htau23 unphosphorylatcd. 
(0) htau23 phosphorylated with GSK3, showing n stoichiometry com- 
parable to the unmodified tnu protein (saturating 0.6 per tubulin 
dimer). (A) Control of htau23 phosphorylated with the brain kinasc 
activity. shotiing a pronounced ecrease instoichiomctry (xc [4]). The 
solid lines show the best fits assuming indcpcndent binding sites. 
We also tested other kinases of the same family to see 
if they had a similar eff’ect as MAP kinase. Kinases of 
this family include the two or more MAP kinase 
isoforms (p42 or p44 MAP kinases, ERKI, ERK2, 
ERK3, for review see [26]), as well as KSSl, cdc2, 
GSK3a and p, and others (for review see [27]). We had 
already shown that cdc2 kinase had no measurable f- 
fect on antibody binding and gel shift. However, it has 
now turned out that GSK3 affects both properties. 
GSK3 was less efficient than MAP kinase in phospho- 
rylating tau. The common feature of both kinases is that 
they phosphorylate Ser-Pro motifs; MAP kindse affects 
Thr-Pro motifs as well, in contrast to GSK3. This is 
possibly explained by the purification and the conccn- 
tration of the enzyme. However, since the antibodies 
and the gel shift assay are mainly sensitive to the phos- 
phorylation status of Ser-Pro motifs, the effects seen by 
SDS-PAGE, immunoblots and autoradiography are 
very similar with both enzymes (Fig. 2), with only minor 
differences that relate mainly to the kinetics of phospho- 
rylation. The GSK3 preparation used in these experi- 
ments was obtained from bovine brain (or as im- 
munoprecipitates from the cytosol of PC12 cells), and 
one could therefore expect to find it in human brain as 
well. This was indeed the case (Fie. 5 and 6). 
Since the physiological function of tau appears to be 
regulated by phosphorylation one would expect a role 
not only for kinases but also for phosphatases. Several 
authors have shown that tau can be phosphorylated by 
several kinases (e.g. PKA, CaM kinase) whose effects 
can be reversed by several phosphatases; this is achieved 
most eficiently by PP-2a (for review see 1281). This 
phosphatasc is also capable of counteracting MAP ki- 
nase and GSK3 (Drewes et al., unpublished). 
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One surprising aspect is that MAP kinasc and GSK3 
are both microtubule-associated proteins (MAPS) as de- 
fined by the classical criterion of co-purification 
through cycles of microtubule assembly; moreover they 
are both associated with PHFs. It has been known for 
a long time that some kinases cycie togeihur wiih micro- 
tubule protein. Since microtubule protein contains tu- 
bulin and various MAPS, the kinases could be associ- 
ated with either one of these components. Both possibil- 
ities seem to occur. Some kinases are bound directly to 
tubulin and phosphorylate ither tubulin-bound GDP 
(NDP kinase, [29]) or tubulin itself (the proto-oncogene 
c-trios, [30]). Others are bound to certain MAPS; the 
classical example is thnt of the RI, subunit of PKA 
attached to MAP2 [It)]. The second case would seem to 
be the most interesting one in the context of Alzheimer 
pathology since a MAP-associated kinase might also 
become PHF associated. Recently, Ishiguro et al. [31] 
described a tubulin-activated kinase that phos- 
phorylated tau, and Vincent and Davies [32] described 
a PHF-associated kinase. Finally, there are kinases as- 
sociated with other cytoskeletal elements (e.g. neurofil- 
aments) which can phosphorylate tau as well [33]. Since 
the phosphorylation sites of these kinase preparations 
are not well defined it is difficult at this moment to relate 
them directly to our findings. 
In conclusion, GSK3 and MAP kinase musl now be 
counted among the microtubule-associated and PHF- 
associated kinases. This is unexpected in view of their 
potentially pathologica! role, but it illustrates that the 
distinction between the ‘normal’ and ‘pathological’ state 
may be very small. GSK3 induces the Alzheimer-like 
characteristics in tau protein in terms of several inde- 
pendent criteria, similar to the ones described for MAP 
kinase [7]. As the name implies, GSK3 phosphorylates 
glycogen synthase and thereby inactivates this enzyme, 
and it phosphorylates other proteins as well, for exam- 
ple the nuclear proto-oncogenes, c-jll/z and c-WZJ& (for 
review see 1341). One of the earliest functions discovered 
was the activation of protein phosphatase- I, hence the 
alternative name of activating factor, FA [8]. Its two 
isoforms 01 and ,6 have been cloned and are highly ho- 
mologous [9]. An interesting feature is that GSK3 often 
operates by a stepwise mechanism that depends on a 
priming phosphorylation by another kinase (for review 
see [35]). In the case of recombinant au this mechanism 
is unlikely, but we cannot exclude it for the phosphoryl- 
ation in viva. In any case, the fact that both MAP kinase 
and GSK3 play an important role in cellular signal 
transduction strengthens the view that the disregulation 
of some signal may eventually be responsible for the 
pathological degeneration of tau protein. 
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